HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: R600016-MCP200v1 6/7/1115    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Caron, M. Articles by Joubert-Caron, R. Search for Related Content PubMed PubMed Citation Articles by Caron, M. Articles by Joubert-Caron, R. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 6:1115-1122, 2007.
© 2007 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Review

Cancer Immunomics Using Autoantibody Signatures for Biomarker Discovery^*

Michel Caron^,, Geneviève Choquet-Kastylevsky^¶ and Raymonde Joubert-Caron

From the Protein Biochemistry and Proteomics Laboratory, UMR CNRS 7033 (BioMoCeTi), Unité de Formation et de Recherche Santé-Médecine-Biologie Humaine, Paris 13 University, 93017 Bobigny cedex, France and ^¶ New Markers Department, Advance Technology Unit, bioMérieux, 69280 Marcy-l'Etoile, France

The increased incidence of autoantibodies in malignancies has been described since the 1970s. Thus the ability to determine molecular fingerprinting of autoantibodies (antibody signatures) may provide useful clinical diagnostic and prognostic information. This review describes the use of several proteomics approaches for the identification of antigens recognized by these autoantibodies. Serological proteome analysis combines separation of tumor cell proteins on two-dimensional gel electrophoresis gels, Western blotting with sera of patients and healthy subjects, and identification of the detected antigens by MS. Alternatively multiple affinity protein profiling combines isolation of the antigens recognized by patient antibodies by two-dimensional immunoaffinity chromatography and identification by MS/MS. The use and limitations of reverse phase protein microarrays for testing patient serum containing autoantibodies are also considered. Lastly the most important difficulty of any proteomically identified autoantibody signature is validation in patient cohorts or clinical samples.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. K. Yi, J. W. Chang, W. Han, J. W. Lee, E. Ko, D. H. Kim, J.-Y. Bae, J. Yu, C. Lee, M.-H. Yu, et al. Autoantibody to Tumor Antigen, Alpha 2-HS Glycoprotein: A Novel Biomarker of Breast Cancer Screening and Diagnosis Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1357 - 1364. [Abstract] [Full Text] [PDF]

				C. M. Story, E. Papa, C.-C. A. Hu, J. L. Ronan, K. Herlihy, H. L. Ploegh, and J. C. Love Profiling antibody responses by multiparametric analysis of primary B cells PNAS, November 18, 2008; 105(46): 17902 - 17907. [Abstract] [Full Text] [PDF]